Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sisunatovir vs placebo in high‑risk adults with RSV infection
jRCT2031230632Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Sisunatovir with Placebo (2 arms). Primary endpoint: RSV-related hospitalization or death from any cause through Day 28 (≤3 days from symptom onset). Started Mar 2024; status: completed.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031230632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230632.